After Achieving All-Time Low, Is resTORbio, Inc. (TORC)’s Near-Term Analysis Positive?

March 18, 2018 - By Richard Conner

The stock of resTORbio, Inc. (NASDAQ:TORC) reached all time low today, Mar, 18 and still has $13.60 target or 9.00 % below today’s $14.95 share price. This indicates more downside for the $406.59M company. This technical setup was reported by If the $13.60 PT is reached, the company will be worth $36.59M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock increased 0.20% or $0.03 during the last trading session, reaching $14.95. About 773,448 shares traded or 288.31% up from the average. resTORbio, Inc. (NASDAQ:TORC) has 0.00% since March 18, 2017 and is . It has underperformed by 16.70% the S&P500.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company has market cap of $406.59 million. The Company’s lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. It currently has negative earnings. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.